Mylan CEO Heather Bresch, holding up EpiPen devices, appeared on Capitol Hill in September 2016 before the House Oversight Committee for a hearing on EpiPen price increases.
Mylan CEO Heather Bresch, holding up EpiPen devices, appeared on Capitol Hill in September 2016 before the House Oversight Committee for a hearing on EpiPen price increases. Pablo Martinez Monsivais The Associated Press
Mylan CEO Heather Bresch, holding up EpiPen devices, appeared on Capitol Hill in September 2016 before the House Oversight Committee for a hearing on EpiPen price increases. Pablo Martinez Monsivais The Associated Press

GOP should focus on drug costs, not Obamacare repeal

January 02, 2017 2:38 PM

Comments